Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model
about
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in miceEvaluation of rifalazil in long-term treatment regimens for tuberculosis in miceEvaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection modelIn vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosisActivity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine modelIn vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosisAnticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cellsHow effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosisRapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.Development potential of rifalazil.Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.Identification of enzymes responsible for rifalazil metabolism in human liver microsomes.
P2860
Q28343604-69441BA8-5899-45C1-AEA5-B296A1FDB047Q28344279-D2EE9356-C930-4F02-9781-CE52C462B8E3Q28344872-637132D0-06AD-422B-81ED-8BFD81BECF79Q28369170-1D64FEEF-20E3-44DE-8012-E01D6B81AEC4Q28378826-B93A5FF6-7414-4B9A-9F47-A602F6973785Q28379169-8DBC6EE3-20AB-41A2-A5E6-54368E05A0BFQ28379172-3DCF09F5-CCD1-4C3B-8E4A-262E14B6C06CQ28379178-36D511A6-F4F2-45EC-8160-351DEE4673CFQ28379180-1F35414C-6AD3-4B39-B60A-52B2C77F84C5Q28379615-FC016D25-2C50-49B1-88D6-D1B1CAD3C0F8Q34823666-AF6E67CE-B4A0-4DA6-AB5B-2DFFF2B5355FQ35056073-03AB8D81-3EDB-450F-A02C-4BF9B6D6C76CQ35122437-C66D7F4C-2EB3-406B-8238-917247DEDFB6Q43505733-80F9A171-5BCD-420A-BA4A-9ED18C7BA7EE
P2860
Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@ast
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@en
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@nl
type
label
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@ast
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@en
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@nl
prefLabel
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@ast
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@en
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@nl
P2093
P2860
P356
P1476
Activity of KRM-1648, a new be ...... tuberculosis in a murine model
@en
P2093
M A Grossi
M H Cynamon
S P Klemens
P2860
P304
P356
10.1128/AAC.38.10.2245
P407
P577
1994-10-01T00:00:00Z